gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              UCB Pharma S.A.

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              SupplySide West

              Participation Not Confirmed

              Update your events

              Phase 3 Data on UCB's Vimpat® CV in Primary Generalized Tonic-Clonic Seizures Published in Journal of Neurology, Neurosurgery & Psychiatry

              Contact the Supplier

              Lead Product(s): Lacosamide

              Therapeutic Area: Neurology Product Name: Vimpat

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2020

              Details:

              Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo.

              UCB Pharma S.A.

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              SupplySide West

              Participation Not Confirmed

              Update your events

              UCB provides an update on Phase 2b padsevonil safety and efficacy study in epilepsy (ARISE)

              Contact the Supplier

              Lead Product(s): Padsevonil

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 13, 2020

              Details:

              ARISE did not reach statistical significance for either of the two primary endpoints.

              PharmaCompass__DigitalAd